| Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial S Ebata, A Yoshizaki, K Oba, K Kashiwabara, K Ueda, Y Uemura, ... The Lancet Rheumatology 3 (7), e489-e497, 2021 | 133 | 2021 |
| Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis T Fukasawa, A Yoshizaki, S Ebata, K Nakamura, R Saigusa, S Miura, ... Arthritis & Rheumatology 69 (9), 1879-1890, 2017 | 61 | 2017 |
| The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition A Enomoto, T Fukasawa, N Takamatsu, M Ito, A Morita, Y Hosoi, ... European journal of cancer 49 (16), 3547-3558, 2013 | 57 | 2013 |
| Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti‐topoisomerase I‐positive systemic sclerosis‐associated interstitial lung disease S Ebata, A Yoshizaki, T Fukasawa, S Miura, T Takahashi, H Sumida, ... The Journal of Dermatology 46 (11), 1006-1013, 2019 | 56 | 2019 |
| Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis A Kuzumi, A Yoshizaki, KM Matsuda, H Kotani, Y Norimatsu, M Fukayama, ... Nature communications 12 (1), 5947, 2021 | 42 | 2021 |
| Cytokine analysis on a countable number of molecules from living single cells on nanofluidic devices T Nakao, Y Kazoe, E Mori, K Morikawa, T Fukasawa, A Yoshizaki, ... Analyst 144 (24), 7200-7208, 2019 | 41 | 2019 |
| Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study KM Matsuda, A Yoshizaki, A Kuzumi, T Fukasawa, S Ebata, S Miura, ... Arthritis research & therapy 21, 1-10, 2019 | 37 | 2019 |
| Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model T Fukasawa, A Yoshizaki, S Ebata, A Yoshizaki-Ogawa, Y Asano, ... Elife 10, e67209, 2021 | 35 | 2021 |
| Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti‐melanoma differentiation‐associated gene 5 antibody … KM Matsuda, A Yoshizaki, A Kuzumi, T Fukasawa, S Ebata, ... The Journal of Dermatology 47 (5), 483-489, 2020 | 26 | 2020 |
| B cell depletion inhibits fibrosis via suppression of profibrotic macrophage differentiation in a mouse model of systemic sclerosis H Numajiri, A Kuzumi, T Fukasawa, S Ebata, A Yoshizaki‐Ogawa, ... Arthritis & Rheumatology 73 (11), 2086-2095, 2021 | 24 | 2021 |
| Serine–Threonine Kinase 38 regulates CDC25A stability and the DNA damage-induced G2/M checkpoint T Fukasawa, A Enomoto, K Miyagawa Cellular Signalling 27 (8), 1569-1575, 2015 | 24 | 2015 |
| Serum interleukin‐34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease A Kuzumi, A Yoshizaki, S Toyama, T Fukasawa, S Ebata, K Nakamura, ... The Journal of dermatology 45 (10), 1216-1220, 2018 | 22 | 2018 |
| Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: Analysis of a single-arm, open-label, phase 1 trial T Fukasawa, A Yoshizaki, S Ebata, M Fukayama, A Kuzumi, Y Norimatsu, ... Journal of the American Academy of Dermatology 89 (2), 366-369, 2023 | 20 | 2023 |
| Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial S Ebata, A Yoshizaki, K Oba, K Kashiwabara, K Ueda, Y Uemura, ... The Lancet Rheumatology 4 (8), e546-e555, 2022 | 20 | 2022 |
| Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial S Ebata, K Oba, K Kashiwabara, K Ueda, Y Uemura, T Watadani, ... Rheumatology 61 (11), 4364-4373, 2022 | 18 | 2022 |
| Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells A Yoshizaki, T Taniguchi, R Saigusa, T Fukasawa, S Ebata, H Numajiri, ... Annals of the Rheumatic Diseases 75 (10), 1858-1865, 2016 | 18 | 2016 |
| Critical contribution of the interleukin‐6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis T Taniguchi, Y Asano, T Fukasawa, A Yoshizaki, S Sato The Journal of dermatology 44 (8), 967-971, 2017 | 16 | 2017 |
| Pharmacotherapy of itch—antihistamines and histamine receptors as G protein-coupled receptors T Fukasawa, A Yoshizaki-Ogawa, A Enomoto, K Miyagawa, S Sato, ... International Journal of Molecular Sciences 23 (12), 6579, 2022 | 13 | 2022 |
| Interleukin (IL)‐17F and IL‐17E are related to fibrosis and vasculopathy in systemic sclerosis M Fukayama, A Yoshizaki, T Fukasawa, S Ebata, A Kuzumi, ... The Journal of Dermatology 47 (11), 1287-1292, 2020 | 12 | 2020 |
| Rapid alteration of serum interleukin‐6 levels may predict the reactivity of iv cyclophosphamide pulse therapy in systemic sclerosis‐associated interstitial lung disease H Numajiri, A Yoshizaki, T Fukasawa, S Ebata, K Nakamura, T Yamashita, ... The Journal of Dermatology 45 (10), 1221-1224, 2018 | 12 | 2018 |
